Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$90.83

-0.66 (-0.72%)

17:01
11/19/17
11/19
17:01
11/19/17
17:01

Galapagos NV reports positive topline results from ALBATROSS with GLPG2222

Galapagos NV reports positive topline results from its ALBATROSS Phase 2 study in cystic fibrosis patients with C1 corrector GLPG2222. The ALBATROSS study included 37 cystic fibrosis patients with a gating mutation on one allele and F508del mutation on the other allele. All patients were on long-term stable Kalydeco treatment at screening and continued their Kalydeco treatment throughout the study. The ALBATROSS study was fully recruited within five months. Primary objectives of this randomized, double-blinded, placebo controlled study were to evaluate the safety and tolerability and pharmacokinetics of novel C1 corrector GLPG2222 in this CF patient population. Once daily doses of 150mg GLPG2222, 300mg GLPG2222 or placebo were administered. Overall, GLPG2222 was well tolerated, with observed treatment emergent adverse events being predominantly mild or moderate, and typical for a CF patient population. There were no serious adverse events reported and no discontinuations due to adverse events. The targeted exposures of GLPG2222 were achieved in this patient study, further strengthening dosing modelling for the first investigational triple combination. Exposures achieved in patients were in line with those observed in healthy volunteers. The additional activity observed with treatment with GLPG2222 on top of Kalydeco was in line with what was observed with tezacaftor combined with Kalydeco in a Phase 2 study in this population. A statistically significant dose dependent decrease in sweat chloride concentration was observed amounting to a decrease of 6 mmol/L in the 300mg cohort. Mean percent predicted FEV1 levels overall were 70% at screening. At the end of treatment with 300mg GLPG2222, ppFEV1 levels increased by 2.2%.

GLPG Galapagos NV
$90.83

-0.66 (-0.72%)

09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
08/14/17
JEFF
08/14/17
NO CHANGE
JEFF
Buy
Expert IPF call positive for FibroGen, says Jefferies
Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.
08/11/17
STFL
08/11/17
UPGRADE
Target $101
STFL
Buy
Stifel upgrades Galapagos with $101 target on 'clearly positive' data
Stifel analyst Adam Walsh upgraded Galapagos NV to Buy from Hold and raised his price target for the shares to $101 from $83. The stock closed yesterday up 11%, or $7.89, to $81.06. The early Phase 2 results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis were "clearly positive," Walsh tells investors in a research note. The analyst included the drug in his model with a "very reasonable" 10% probability of success. Further, he sees "reduced downside risk" associated with Galapagos' cystic fibrosis triple combo.

TODAY'S FREE FLY STORIES

CSX

CSX

$52.93

-4.38 (-7.64%)

15:18
12/16/17
12/16
15:18
12/16/17
15:18
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

CBOE Holdings

$126.37

0.31 (0.25%)

11:22
12/16/17
12/16
11:22
12/16/17
11:22
Periodicals
CBOE should not be treated as 'set and forget,' Barron's says »

Bitcoin futures have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

11:17
12/16/17
12/16
11:17
12/16/17
11:17
Periodicals
Disney/Fox 'a murky web of deals within deals,' Barron's says »

Walt Disney's (DIS)…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$70.83

1.44 (2.08%)

10:53
12/16/17
12/16
10:53
12/16/17
10:53
Periodicals
Alaska air should bounce back in 2018, Barron's says »

While shares of Alaska…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

10:42
12/16/17
12/16
10:42
12/16/17
10:42
Periodicals
Spark Therapeutics selloff may be overdone, Barron's says »

Spark Therapeutics shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jan

AAPL

Apple

$173.97

1.75 (1.02%)

10:29
12/16/17
12/16
10:29
12/16/17
10:29
Periodicals
New Apple iPhone features also bring software bugs, Barron's says »

While each new Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

10:19
12/16/17
12/16
10:19
12/16/17
10:19
Periodicals
More consolidation to come after Disney/Fox deal, Barron's says »

Netflix (NFLX) success…

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

09:22
12/16/17
12/16
09:22
12/16/17
09:22
Periodicals
Exxon disclosure of climate-change regulation impact has risks, Barron's says »

In a filing with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

07:58
12/16/17
12/16
07:58
12/16/17
07:58
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

T

AT&T

$38.24

0.5 (1.32%)

CHTR

Charter

$322.31

-6.37 (-1.94%)

CMCSA

Comcast

$39.71

0.59 (1.51%)

CMCSK

Comcast

VZ

Verizon

$52.67

0.33 (0.63%)

NFLX

Netflix

$190.12

0.56 (0.30%)

AMZN

Amazon.com

$1,179.14

4.88 (0.42%)

FB

Facebook

$180.18

1.79 (1.00%)

TWTR

Twitter

$22.23

-0.35 (-1.55%)

GOOG

Alphabet

$1,064.19

15.04 (1.43%)

GOOGL

Alphabet Class A

$1,072.00

14.53 (1.37%)

DFS

Discover

$74.59

0.92 (1.25%)

SYF

Synchrony

$37.19

0.2 (0.54%)

COF

Capital One

$96.31

2.25 (2.39%)

OMF

OneMain Holdings

$25.50

0.25 (0.99%)

CIT

CIT Group

$49.78

0.64 (1.30%)

SC

Santander Consumer

$17.99

-0.29 (-1.59%)

SLM

Sallie Mae

$11.17

0.18 (1.64%)

AL

Air Lease

$45.80

1.07 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 14

    Dec

SHOO

Steven Madden

$44.15

1.15 (2.67%)

04:55
12/16/17
12/16
04:55
12/16/17
04:55
Conference/Events
Steven Madden management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 07

    Jan

  • 08

    Jan

STLD

Steel Dynamics

$39.85

0.01 (0.03%)

18:07
12/15/17
12/15
18:07
12/15/17
18:07
Earnings
Steel Dynamics sees Q4 EPS 48c-52c, consensus 55c »

"Despite a lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

House plans to vote…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Republicans release final tax bill proposal, CNBC reports »

Republicans have released…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$162.60

5.4 (3.44%)

17:37
12/15/17
12/15
17:37
12/15/17
17:37
Hot Stocks
McKesson awarded $400M government contract »

McKesson has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$60.94

0.11 (0.18%)

17:34
12/15/17
12/15
17:34
12/15/17
17:34
Syndicate
Breaking Syndicate news story on Ameren »

Ameren files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$57.76

1 (1.76%)

, AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

17:33
12/15/17
12/15
17:33
12/15/17
17:33
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Akamai (AKAM), up…

AKAM

Akamai

$57.76

1 (1.76%)

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

PG

Procter & Gamble

$91.89

0.89 (0.98%)

PETX

Aratana Therapeutics

$5.73

0.15 (2.69%)

HPE

HP Enterprise

$14.41

0.17 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 13

    Dec

GRMN

Garmin

$58.36

-1.1 (-1.85%)

17:32
12/15/17
12/15
17:32
12/15/17
17:32
Recommendations
Garmin analyst commentary at Tigress Financial »

Garmin growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$322.82

5.81 (1.83%)

17:26
12/15/17
12/15
17:26
12/15/17
17:26
Hot Stocks
Lockheed Martin awarded $135.83M government contract »

Lockheed Martin is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

PG

Procter & Gamble

$91.89

0.89 (0.98%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
Peltz to join Procter & Gamble board effective March 1, 2018 »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.89 (0.98%)

, NVS

Novartis

$84.86

0.39 (0.46%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
P&G names Trian's Nelson Peltz, Novartis CEO Jimenez to board »

Procter & Gamble (PG)…

PG

Procter & Gamble

$91.89

0.89 (0.98%)

NVS

Novartis

$84.86

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 17

    May

SNSS

Sunesis

$3.36

0.16 (5.00%)

17:16
12/15/17
12/15
17:16
12/15/17
17:16
Hot Stocks
Sunesis CEO Swisher to resign, Dayton Misfeldt named interim CEO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, BA

Boeing

$293.94

0.06 (0.02%)

17:09
12/15/17
12/15
17:09
12/15/17
17:09
Hot Stocks
AT&T CEO Stephenson resigns from Boeing board »

According to a regulatory…

T

AT&T

$38.24

0.5 (1.32%)

BA

Boeing

$293.94

0.06 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

HPE

HP Enterprise

$14.41

0.17 (1.19%)

17:03
12/15/17
12/15
17:03
12/15/17
17:03
Syndicate
Breaking Syndicate news story on HP Enterprise »

HP Enterprise files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

FSV

FirstService

$67.87

-0.54 (-0.79%)

17:02
12/15/17
12/15
17:02
12/15/17
17:02
Hot Stocks
Breaking Hot Stocks news story on FirstService »

Jay S. Hennick reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETP

Energy Transfer Partners

$17.50

0.08 (0.46%)

17:01
12/15/17
12/15
17:01
12/15/17
17:01
Hot Stocks
Energy Transfer gets FERC approval to place Rover Pipeline's 1B into service »

Energy Transfer Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.